« Back to Record
Nuciforo, P. G., Aura, C. M., Holmes, E., Prudkin, L., Molina Jimenez, J., Martinez Aznar, P., de la Peña, L., Ellis, C., Eidtmann, H., Piccart-Gebhart, M., Scaltriti., M., & Baselga, J. (2015). Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status. Annals of oncology, 26(7), 1494-1500. doi:10.1093/annonc/mdv175
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/229173



